PEG

Lulizumab pegol (BMS-931699) is an anti-CD28 antibody antagonist that inhibits T-cell proliferation, offering potential therapeutic applications for kidney transplantation and autoimmune disease research [1].

Azido-PEG3-maleimide is a PEG-based PROTAC linker used primarily for the synthesis of PROTACs[1] and also functions as a cleavable 3-unit PEG ADC linker in the synthesis of antibody-drug conjugates (ADCs)[2].

endo-BCN-PEG8-acid, a PEG-based linker, is pivotal for PROTAC molecules, connecting two essential ligands and facilitating selective protein degradation via the ubiquitin-proteasome system within cells.

Biotin-PEG-Biotin (MW 1000) is a PEG-derived PROTAC linker utilized in PROTAC synthesis [1].

Gly-Gly-Gly-PEG4-DBCO is a degradable ADC linker containing 4 units of PEG, which can be used to synthesize antibody-conjugated active molecules (ADCs).

Mal-amido-PEG12-acid is a PEG-based linker for PROTACs, facilitating the formation of PROTAC molecules by connecting two essential ligands and enabling selective protein degradation via the ubiquitin-proteasome system within cells.

Propargyl-PEG3-amine (Propargyl-PEG3-NH2) is a PROTAC linker belonging to the PEG class and can be used to synthesize PROTAC molecules.

DBCO-PEG4-tri-(carboxyethoxymethyl)-methane constitutes a branched PEG linker that includes DBCO for copper-free click reactions and three terminal carboxyl groups for reacting with primary amines in the presence of activators like HATU. The PEG linkers bolster the hydrophilicity of the molecule. Reagent grade, for research purpose

Certolizumab pegol (Certolizumab) is a recombinant, humanized monoclonal antibody fragment modified with polyethylene glycol (PEG), selectively targeting and neutralizing tumor necrosis factor-alpha (TNF-α). This compound is utilized in research for rheumatoid arthritis and Crohn's disease [1] [2].